Issue 58

Is the NHS ready to embrace psychedelics as medicine?

Awakn Life Sciences recently signed a memorandum of understanding with Devon Partnership NHS Trust and the University of Exeter, to assess the NHS’s readiness to adopt ketamine-assisted therapies.

The creation of the partnership indicates that the NHS is willing to explore and embrace psychedelic-assisted therapies, which could expedite their regulatory approval in the UK.

To learn more about the agreement, PSYCH sat down with Professor Celia Morgan, head of ketamine-assisted psychotherapy for addiction at Awakn Life Sciences.

Read More

DEA AGAIN BOOSTS 2022 PRODUCTION GOALS FOR PSYCHEDELIC MEDICINES

In support of psychedelic healthcare, the DEA now wants 8.2kg of MDMA and 8kg of psilocybin to be produced in 2022.

Read More

MAPS AND VINE VENTURES RAISE US$70M THROUGH REVENUE SHARING MODEL

MAPS and Vine Ventures enter agreement to inject capital for research into MDMA-assisted therapy.

Read More

BUSINESS AND INVESTMENT

GH Research shares Q3 2021 financial results.

Gwella builds platform on functional health, mushrooms and psychedelics.

Mycotopia and Ei.Ventures sign LOI to explore merger.

Will psychedelics become mainstream? This Calgary company is betting on it.

Cognetivity Neurosciences partners with Ketamine One on clinical trials.

Psirenity enters psilocybin licence agreement with New Leaf.

Mydecine files patents for psilocin analogues.

HealthDay: A patient’s experience of psilocybin therapy.

US government to test Delix’s ibogaine derivative as addiction treatment.

FDA confirms Tryp can continue Phase II trial.

Psilera shares data from preclinical trials.

Algernon manufactures DMT for clinical trials.

Novamind opens clinic focused on substance misuse disorder.

Michael Falvey joins COMPASS as CFO.

SCIENCE AND RESEARCH

Blossom research briefing: improving psychedelic trials.

Professor David Nutt explains how psychedelic therapy works.

People ‘microdosing’ on psychedelics to improve well-being during pandemic.

Can psychedelics cure addiction?

Researchers to test psilocybin in healthcare workers affected by pandemic.

Are psychedelics the next big treatment for depression?

Study finds psychedelics boost mood and reduce anxiety and depression.

DMT: a trip to get away from depression?

University of Victoria: psychedelics revisited.

Psychedelics are poised to change the course of mental health treatment.

Are psychedelics superior for treating mental illness?

Psychedelics: new frontier for mental health conditions?

At the PSYCH Investor Summit: Research and Technology, MAPS’ founder Rick Doblin and atai Life Sciences founder Christian Angermayer discussed the intersection of for-profit and non-profit psychedelic organisations.

View the one-on-one discussion

REGULATION AND LEGISLATION

Psychedelic compounds could become legal in California.

Psilocybin edges towards mainstream therapy.

Should psychedelics be legal? Users claim they are ‘life saving’ but ‘traumatising’.

Partner with us